Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety – HCPLive

In an interview with HCPLive, Daniel Karlin, MD, discussed how their phase 2B trial demonstrated MM120’s durability through week 12 for the …